Twist Bioscience revenue and financials
$205.00Change from previous close: +8.66%Absolute change: +$16.33
In the fiscal year ended September 2025, Twist Bioscience reported revenue of $376.57M (+20.32% year over year). The net loss was $77.67M.
Fiscal year ending in September. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +20.32%
- FY to Sep 2025 vs FY to Sep 2024
- Net margin
- -20.6%
- FY to Sep 2024: -66.7%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1.1 | -17.6 | -24.8 | -11.8 | -1.4 | -13.0 | -21.4 | -15.3 | -6.4 | -19.4 | -23.0 | -20.7 |
| Depreciation and amortization | 6.5 | 6.2 | 5.9 | 3.9 | 5.8 | 6.2 | 6.1 | 4.1 | 8.3 | 8.3 | 8.2 | 7.6 |
| Capital expenditure | -9.8 | -7.9 | -10.0 | -12.4 | -9.2 | -4.1 | -2.3 | -2.0 | -1.0 | -0.6 | -1.5 | -2.4 |
| Investing cash flow | -10.2 | -12.7 | -9.9 | -12.4 | -9.4 | -1.4 | -1.5 | -1.3 | -0.7 | -5.2 | 4.2 | -2.2 |
| Financing cash flow | 3.8 | 4.1 | 0.3 | 5.6 | 1.8 | 3.2 | 17.9 | 3.6 | 2.9 | 1.8 | -1.5 | 0.4 |
| Share repurchases | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 | -1.5 | -2.4 | -1.1 |
| Effect of exchange rates | 0.0 | -0.0 | 0.0 | 0.2 | -0.1 | 0.1 | -0.1 | 0.1 | 0.0 | -0.1 | 0.1 | -0.0 |
| Net change in cash | -5.3 | -26.1 | -34.4 | -18.5 | -9.0 | -11.1 | -5.1 | -12.9 | -4.2 | -22.9 | -20.2 | -22.6 |
| Free cash flow | -8.6 | -25.4 | -34.8 | -24.2 | -10.6 | -17.1 | -23.7 | -17.3 | -7.3 | -20.0 | -24.5 | -23.1 |
| Levered free cash flow | -8.1 | -16.3 | -25.9 | -14.6 | -1.7 | -5.1 | -11.2 | -6.5 | 6.0 | -6.0 | -10.9 | -12.0 |